A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive HER2 Negative Advanced Breast Cancer
Brief description of study
The purpose of the study is to look at the safety and tolerability for immunotherapy combinations to determine how these drugs work for participants with ER-positive, HER2-negative breast cancer. All study arms include Nivolumab and Nab-Paclitaxel.
Clinical Study Identifier: s19-01350
ClinicalTrials.gov Identifier: NCT04132817
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
